Patent · US Active

T cell receptors and immune therapy using the same

US10725044B2 · kind B2 · utility

1Cited by

0References

30Claims

0Family size

Assignee

Immatics Biotechnologies GmbH · DE

Inventors

Leonie ALTEN · Lörrach, DE
Sebastian BUNK · Wien, AT
Dominik MAURER · Lingen (Ems), DE
Claudia WAGNER · Lörrach, DE

Key dates

Filing date	Jul 2, 2018
Grant date	Jul 28, 2020
Priority date	—
Expiry date	Jul 2, 2038

Classification

Technology area (CPC G)Physics
CPC primaryG01N33/58
WIPO fieldPharmaceuticals
WIPO sectorChemistry

Abstract

The present invention relates to antigen recognizing constructs against a tumor associated antigen (TAA) derived from the target protein DDB1 and CUL4 associated factor 4-like 2 (DCAF4L2). The invention in particular provides novel T cell receptor (TCR) based molecules which are selective and specific for the TAA of the invention. The TCR of the invention, and TAA binding fragments derived therefrom, are of use for the diagnosis, treatment and prevention of TAA expressing cancerous diseases. Further provided are nucleic acids encoding the antigen recognizing constructs of the invention, vectors comprising these nucleic acids, recombinant cells expressing the antigen recognizing constructs and pharmaceutical compositions comprising the compounds of the invention.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.